Laboratory evaluation demonstrates that C-type natriuretic peptide suppresses pericyte dysfunction in pulmonary arterial hypertension, suggesting a novel therapeutic pathway.
Key Points
C-type natriuretic peptide prevents growth factor-induced proliferation and migration in human pulmonary arterial hypertension pericytes by activating FoxO3 signaling.
Laboratory analysis of patient lung pericytes demonstrates that antiproliferative signaling acts through protein kinase I and cGMP to block PI3K/AKT activity.
Human cell model; further preclinical work is needed, but augmenting CNP and cGMP pathways highlights a viable therapeutic strategy against vascular remodeling.